𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mechanisms of osteolytic bone metastases in breast carcinoma

✍ Scribed by Sanna-Maria Käkönen; Gregory R. Mundy

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
102 KB
Volume
97
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Osteolytic and osteoblastic metastases are often the cause of considerable morbidity in patients with advanced prostate and breast carcinoma. Breast carcinoma metastasis to bone occurs because bone provides a favorable site for aggressive behavior of metastatic cancer cells. A vicious cycle arises between cancer cells and the bone microenvironment, which is mediated by the production of growth factors such as transforming growth factor beta and insulin growth factor from bone and parathyroid hormone-related protein (PTHrP) produced by tumor cells. Osteolysis and tumor cell accumulation can be interrupted by inhibiting any of these limbs of the vicious cycle. For example, bisphosphonates (e.g., pamidronate, ibandronate, risedronate, clodronate, and zoledronate) inhibit both bone lesions and tumor cell burden in bone in experimental models of breast carcinomametastasis. Neutralizing antibodies to PTHrP, which inhibit PTHrP effects on osteoclastic bone resorption, also reduce osteolytic bone lesions and tumor burden in bone. Other pharmacologic approaches to inhibit PTHrP produced by breast carcinoma cells in the bone microenvironment also produce similar beneficial effects. Identification of the molecular mechanisms responsible for osteolytic metastases is crucial in designing effective therapy for this devastating complication.

📜 SIMILAR VOLUMES

Molecular mechanisms of osteolytic bone
Molecular mechanisms of osteolytic bone metastases
✍ Theresa A. Guise 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

## BACKGROUND. Breast carcinoma commonly metastasizes to the skeleton in patients with advanced disease to cause bone destruction and the associated pain, hypercalcemia, fracture, and nerve-compression syndromes. In this scenario, the bone destruction is mediated by the osteoclast. Tumor-produced

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who

Breast cancer-derived Dickkopf1 inhibits
Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases
✍ Guojun Bu; Wenyan Lu; Chia-Chen Liu; Katri Selander; Toshiyuki Yoneda; Christoph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 494 KB 👁 2 views

## Abstract Most breast cancer metastases in bone form osteolytic lesions, but the mechanisms of tumor‐induced bone resorption and destruction are not fully understood. Although it is well recognized that Wnt/β‐catenin signaling is important for breast cancer tumorigenesis, the role of this pathway